Novogene Acquires an Illumina HiSeq X Ten Sequencing System

First-in-China Deal Increases Novogene’s Investment in Illumina’s Next-Generation Sequencing Technology

SAN DIEGO--(BUSINESS WIRE)--Feb. 13, 2014-- Illumina, Inc. (NASDAQ:ILMN) today announced that Novogene (www.novogene.cn), a leading genomics service provider based in Beijing, China, purchased one HiSeq X Ten. This strategic investment expands Novogene’s capacity with Illumina’s next-generation sequencing systems, which also includes HiSeqs and MiSeqs.

“The HiSeq X Ten will enhance our capability for cancer genomics and for mapping human disease genes, while enabling us to do population sequencing,” said Dr. Ruiqiang Li, CEO of Novogene.

“We are excited Novogene is investing in the HiSeq X Ten to further accelerate cancer and genetic disease research in China,” said Jay Flatley, CEO of Illumina. “Novogene’s portfolio provides the power to conduct the full range of next-generation sequencing applications from population scale sequencing, on the HiSeq X Ten, to exomes, targeted panels and RNA applications on HiSeq and MiSeq.”

The HiSeq X Ten is the world’s first platform to deliver full coverage human genomes for less than $1,000, including typical instrument depreciation, DNA extraction, library preparation, and estimated labor. Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten can sequence tens of thousands of samples annually with high-quality, high-coverage sequencing. It is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than three days or up to 600 gigabases (Gb) per day, per system.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com